Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LifeTech Scientific Corporation ( (HK:1302) ) just unveiled an announcement.
LifeTech Scientific Corporation has issued a supplemental announcement detailing pricing considerations for a connected share purchase under its share award scheme, following earlier transactions in June 2024 and December 2025. The company explains that the HK$1.900 per share consideration was based on medium- to long-term trading averages rather than a temporarily depressed market price.
Management cites sector-wide pressure on Hong Kong-listed medical device stocks after Beijing launched volume-based procurement for electrophysiology and neuro-intervention consumables, which weighed on valuations and the Hang Seng Healthcare Index. LifeTech argues the agreed price, set at a small premium to recent averages, strikes a balance between fair value, cost efficiency and the support of chairman and CEO Xie Yuehui, reinforcing confidence in its long-term development and aligning the transaction with shareholders’ interests.
The company also reiterates that the June 2024 share purchase at HK$1.500 per share was executed at a modest premium to short-term trading averages at that time. By framing both transactions as consistent with market references despite temporary volatility and relatively thin liquidity in its stock, LifeTech aims to reassure stakeholders that its share award scheme purchases are reasonably priced and supportive of its strategic growth plans.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation is a Hong Kong-listed medical device company focused on interventional products, including electrophysiology and neuro-intervention consumables such as coils, intracranial stents and flow-diverting dense-mesh stents. The group targets the healthcare market in mainland China and abroad, with its shares traded under stock code 1302 on the Hong Kong Stock Exchange.
Average Trading Volume: 32,434,717
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.3B
For detailed information about 1302 stock, go to TipRanks’ Stock Analysis page.